Atomoxetine plus oxybutynin for obstructive sleep apnoea: a randomised-controlled trial with detailed pathophysiology

Le résumé fourni par la source

Rationale Obstructive sleep apnoea (OSA) is a prevalent disorder with major health consequences for which there is no approved pharmacological therapy targeting upper airway muscle pathophysiology. A combination of a noradrenergic (atomoxetine) and antimuscarinic (oxybutynin) (AtoOxy) may meaningfully reduce apnoea-hypopnoea index (AHI), but further repeated-dose intervention data are needed. Methods 58 participants with moderate-to-severe OSA were randomised to receive AtoOxy (80/5 mg) and placebo in a 1-month cross-over study. Primary analysis quantified the effect of AtoOxy versus placebo on AHI (percent change from baseline). Individual pathophysiology was characterised at baseline in a stand-alone gold-standard physiology study to determine whether OSA traits (collapsibility per ‘Pcrit’; arousal threshold and muscle effectiveness per intraoesophageal catheter; loop gain) modified AtoOxy effectiveness. Results AHI was lowered by −23.8 (−35.2, −10.6)% baseline (estimate (95% CI)) with AtoOxy versus by −11.7 (−24.3, 2.9)% baseline with placebo; the treatment difference of −12.1 (−22.4, −0.5)% baseline was significant (p=0.041). Only arousal threshold was a significant modifier of response: AtoOxy treatment effect was greater in high versus low arousal threshold (−25 vs +3 % baseline treatment difference from placebo). Point-estimate treatment differences were observed within low but not high muscle effectiveness (−20 vs −4 % baseline ) and mild but not severe collapsibility (−17 vs −7 % baseline ). Sensitivity analysis suggested a twofold greater treatment difference using AHI 4 (4% hypopnoea criteria). Conclusions AtoOxy reduced AHI over 1 month; although the average response was not clinically meaningful, greater improvements were observed in participants with a higher arousal threshold, lower muscle effectiveness and milder collapsibility, which could enable targeted pharmacological intervention.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.